/
/
Patient Power: Is Maintenance Therapy Necessary for MRD Negative Patients?
Patient Power: Is Maintenance Therapy Necessary for MRD Negative Patients? image
Patient Power: Is Maintenance Therapy Necessary for MRD Negative Patients?
Posted Jan 14, 2019

When a multiple myeloma patient achieves a negative MRD test, it doesn’t necessarily mean that the patient is cured, but it does mean that the most sensitive testing available does not detect myeloma--which is a very good thing.

Dr. Gareth Morgan from the UAMS Myeloma Institute noted that this stage is “a very good endpoint…but, it’s not an endpoint that says ‘stop treatment’.”

Several studies, including the ixazomib maintenance data, have shown that even with an MRD negative test, receiving maintenance therapy approves a patient’s outcome even further.

"We have to be thinking about patients' quality of life, durability of on-going therapy, total cost--but actually, I think within the cost envelope we have now, I think there's a lot of room for maneuver that really is going to see patients patent that progression for an overall survival pushed out, so very good numbers." -Dr. Morgan.

 

See full video.

The author Erika Johnson

about the author
Erika Johnson

Myeloma Crowd Editorial Contributor, Nursing student, and cancer advocate.

More Life with Myeloma Articles

Get the latest thought leadership on Myeloma delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for Myeloma Newsletter" for Myeloma news, life with Myeloma stories, Myeloma clinical trials, Myeloma 101 articles and events with Myeloma experts.

Thanks to our HealthTree Community for Myeloma Sponsors:

Genentech
Abbvie
Bristol Myers Squibb
Janssen Oncology
GSK

Follow Us

facebook instagram twitter youtube

Copyright © 2022 HealthTree Foundation. All Rights Reserved.

The HealthTree Foundation / Myeloma Crowd is a qualified 501(c)(3) tax-exempt organization. Tax ID 45-5354811

 https://www.guidestar.org/profile/45-5354811